Neuropathix

Neuropathix Announces Publication of Validated Preclinical Studies on #KLS13019 in the British Journal of Pharmacology #NPTX #neuropathix #nlrp3 #inflammasome #antiinflammatory

New Paper Published on Neuropathix patented molecule KLS-13019 on its Prevention and Reversal of Neuropathic Pain and much more. This tells us that KLS-13019 has benefits beyond its ability to alleviate pain, Dr. Ward said. Congrats to our whole team on this groundbreaking work of Drs. Ward, Brenneman, Kinney, McDonnell.

Neuropathix Chief Scientist William Kinney is the Featured Speaker at Drug Discovery Webinar on Improving on Cannabinoids in Nature in Terms of Safety, Specificity Bioavailability and Efficacy details below. https://scholarsconferences.com/drugdiscov/keynote-speakers

Neuropathix CEO Recaps 2020 Advances and Potential Ahead $NPTX #NPTX #neuropathix #kls13019 #nlrp3 #inflammasome #antiinflammatory #nptx204 #kannalife #neuroprotectant #neuroprotective #nonopioid #and302 #and383 #atopidine #lea #painmanagement #opioidreplacements #opioidreplacement

Neuropathix scores patent for PUFA neuroprotectant to combat oxidative stress (Featured in Nutrition Insight) #NPTX #neuropathix #kls13019 #kannalife #cannabinoid #anticonvulsant #epilepsy #neuroprotectant #nonopioid #opioidcrisis #opiodalternative #painmanagement #chronicpain #pain #patented #technology #pharma #biotech #biotechnology #cannabinoids

Neuropathix Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant #NPTX #neuropathix #nptx204 #kls13019 #kannalife #hulumuslupulus #hops #cannabinoids #cannabidiol #cbd #neuroprotectant #patent

Neuropathix Appoints World-Renowned Pain Management Clinician Dr. Daniel Richman to the Company’s Scientific Advisory Board We are excited to welcome Dr. Richman on our team! #NPTX #neuropathix #kls13019 #kannalife #biotechnology #biotech #nonopioid #cannabinoid #cannabidiol #CBD #neuroprotectant #oxidativestress #neurodegeneration #chronicpain

Neuropathix Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate #NPTX #neuropathix #kls13019 #kannalife #cannabinoid #anticonvulsant #epilepsy #neuroprotectant #nonopioid #opioidcrisis #opiodalternative #painmanagement #chronicpain #pain #patented #technology #pharma #biotech #biotechnology #cannabinoids

I wanted to extend an invitation for you to attend the Neuropathix Presentation at the 13th Annual LD Micro Main Event, taking place online Tuesday, December 15, 2020 @ 10am EST. Neuropathix CEO Dean Petkanas will present a 10 minute presentation at this event, followed by 10 minutes of Q&A from a panel of analysts and investors.... The conference will feature more than 250 companies in the small- and micro-cap space, with tens of thousands of investor participants, as well as speakers such as Shaquille O’Neal. For more information, or to register for the conference, click to register below:

Neuropathix CEO Dean Petkanas featured in European Pharmaceutical Review discusses a CBD-inspired molecule can offer an improved therapeutic value $NPTX #NPTX #neuropathix #kls13019 #kannalife #cannabinoid #epilepsy #nonopioid #patented #pain #pharma #biotech #biotechnology

Neuropathix Signs Binding Letter of Intent to Acquire Anticonvulsant Neuroprotective Intellectual Property #NPTX #neuropathix #kls13019 #kannalife #cannabinoid #anticonvulsant #epilepsy #neuroprotectant #nonopioid #opioidcrisis #opiodalternative #painmanagement #chronicpain #pain #patented #technology #pharma #biotech #biotechnology #cannabinoids